Randomized trial · people

Tirzepatide beat semaglutide 1 mg on HbA1c at 40 weeks in SURPASS-2

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a direct comparison with semaglutide 1 mg, all three tirzepatide doses lowered HbA1c and body weight more, and stomach side effects were the most common complaint with both drugs.

Kind
Randomized trial
Studied in
People
Number studied
1879
Published
2021
Journal
N Engl J Med

What they tested

The team wanted to know whether once-weekly tirzepatide lowers blood sugar at least as well as, or better than, once-weekly semaglutide in people with type 2 diabetes.

How the study was done

An open-label (everyone knew which drug they got), randomized, phase 3 trial that split 1879 patients with type 2 diabetes evenly into tirzepatide 5 mg, 10 mg or 15 mg arms or a semaglutide 1 mg arm for 40 weeks. Participants were 56.6 years old and weighed 93.7 kg on average, and their HbA1c (a 3-month average of blood sugar) averaged 8.28% when the trial began.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

HbA1c fell by an estimated 2.01, 2.24 and 2.30 percentage points in the 5 mg, 10 mg and 15 mg tirzepatide arms, compared with 1.86 points in the semaglutide arm. Next to semaglutide, the extra drop was 0.15, 0.39 and 0.45 points, so every tirzepatide dose was both noninferior (no worse) and superior. Weight loss was also greater with tirzepatide, by an estimated 1.9 kg, 3.6 kg and 5.5 kg across the three doses. Stomach side effects were the most common and mostly mild to moderate, with nausea in 17 to 22% on tirzepatide and 18% on semaglutide; low blood sugar under 54 mg per deciliter was reported in 0.2% to 1.7% on tirzepatide and 0.4% on semaglutide, and serious adverse events in 5 to 7% on tirzepatide and 3% on semaglutide.

What it doesn’t show

Patients and doctors knew which drug was given, the trial ran 40 weeks, and tirzepatide was compared only with semaglutide at 1 mg. The trial was funded by Eli Lilly.

The paper

Frías et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021.

The compounds

More studies on Tirzepatide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking tirzepatide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo